Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Context Therapeutics Inc.NASDAQ: CNTX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $4.69K rose 15.6% year over year, behind the +36.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 15.3% from the prior quarter. Over 3 fiscal years it compounded at +20.6% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +15.6% toward the trailing-twelve-month pace of +36.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.69K+15.3% QoQ
Last fiscal yearDec 2025
$16.25K+49.4% YoY
LTMMar 2026
$16.88K+36.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.6%——
1 year+49.4%——
3-year CAGR+20.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
16.25K USD
Year-over-year change
+49.4%

Depreciation & Amortization vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +36.5% is the 2nd highest of 10, against a peer median of -11.2%.
  • Over three fiscal years its annual growth of +20.6% compares with a peer median of -12.3%.
CNTX Competitors
Depreciation & Amortization for CNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$6.94M USD-7.1%-22.5%4.4%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
CLNNClene Inc.LTM Mar 2026$1.45M USD-11.2%+13.6%1079.1%
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.4%1100.0%
IMAImageneBio IncLTM Mar 2026$616K USD+72.1%-24.1%—
IFRXInflaRx N.V.LTM Mar 2026€377.74K EUR-20.5%-12.3%1287.9%
OVIDOvid Therapeutics Inc.LTM Mar 2026$168K USD-72.2%-41.8%2.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$121K USD-27.5%+27.8%—
WHWKWhitehawk Therapeutics IncLTM Dec 2025$79K USD-59.1%-20.8%1.1%
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$16.88K USD+36.5%+20.6%—
Peer median (excluding CNTX) —-11.2%-12.3%364.3%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Depreciation & Amortization09.27K12.04K10.88K16.25K
Deferred Income Tax00000
Stock-Based Compensation511.08K976.44K1.08M841.87K1.33M
Change in Working Capital(2.22M)(277.52K)1.78M(3.48M)6.28M
Accounts Receivables00000
Inventory00000
Accounts Payables(866.01K)(787.89K)1.45M(946K)1.1M
Other Working Capital(1.36M)510.37K329.03K(2.53M)5.19M
Other Non-Cash Items3.37M578.52K51.97K14.79M2.11M
Operating Cash Flow(8.8M)(13.55M)(21.05M)(14.56M)(26.39M)
Capital Expenditures(250K)(536.84K)0(14.76M)(33.95K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities000(14.75M)(2M)
Investing Cash Flow(250K)(536.84K)0(14.76M)(2.03M)
Debt Repayment00000
Common Stock Issued53.41M(102.07K)0109.29M(15.27K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow58.39M(102.07K)0109.29M(15.27K)
Effect of Forex Changes050.39K000
Net Change in Cash49.34M(14.14M)(21.05M)79.98M(28.43M)
Free Cash Flow(9.05M)(14.09M)(21.05M)(29.31M)(26.42M)

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.